Camillo Ricordi, MD, FNAI, outlines what needs to happen next in the islet transplantation field.
Several preclinical models exist that demonstrate induction of local immunosuppression, said Camillo Ricordi, MD, FNAI, a professor and director of the Diabetes Research Institute and Cell Transplant Center at the University of Miami, Florida.
Transcript
What are the next steps for research into islet transplantation for type 1 diabetes?
The next step will be to continue to try to define strategies that will use less immunosuppression and tolerance induction. There are several preclinical models that are extremely promising both inducing local immunosuppression, local immunomodulation, at the site of transplantation, [and] working on models, like we started doing clinically, putting islets in [inaudible] instead of the liver that provide a confined space that you can manipulate. Also as far as tissue engineering with immunomodulatory molecules, you can use these trials combining mesenchymal stem cells, which are also immunomodulator and anti-inflammatory. And you will see a trial with regulatory T cells expanded to block progression of autoimmunity but also to help to induce transplant tolerance.
These are on one front. One front will be immunomodulation and tolerance induction in the absence of chronic recipient immunosuppression. And on the other side will be defining better and improved sources of stem cell–derived insulin-producing cells to provide enough supply to transplant all the patients who may benefit from these procedures.
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Accessing pediatric dermatology care is challenging due to a shortage of specialists and general dermatologists' reluctance to treat children, but increasing their comfort level with seeing children could help bridge the gap, explained Elizabeth Garcia Creighton, of University of Colorado School of Medicine.
Read More
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More